A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects
Latest Information Update: 17 Jun 2022
At a glance
- Drugs VLX-1005 (Primary)
- Indications Heparin-induced thrombocytopenia and thrombosis syndrome
- Focus Adverse reactions; First in man
- Sponsors Veralox Therapeutics
- 13 Jun 2022 Results presented in a Veralox Therapeutics Media Release.
- 26 Apr 2022 Status changed from recruiting to completed.
- 30 Jun 2021 Status changed from not yet recruiting to recruiting.